Skip to main content
SpringerLink
Log in

Cdc25 as a Potential Target of Anticancer Agents

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Ever since its discovery in yeast more than a decade ago [1], Cdc25has continued to surprise and intrigue researchers. Thisdual-specificity protein tyrosine phosphatase (dsPTPase) and other members of the protein tyrosine phosphatase family (PTPases) have only recently joined the protease and kinase enzyme families in drugdiscovery efforts. The role of phosphatases in tumourigenesis wasreviewed recently by Parsons [2]. He is arguing that the phosphatasefamily of enzymes is involved in a variety of cancers and thus poses both a challenge and an opportunity for new therapeutics. The general biology and biochemistry of Cdc25 were recently reviewed [3].

Here I shall first summarize the recent literature on the role ofCdc25 in disease, as well as on new insights into the regulation of thisfamily of proteins. In the second part, I will review current knowledge ofthe Cdc25 protein structure and the chemical structures and activities of published Cdc25 inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Russell P, Nurse P: cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell 45(1): 145–153, 1986.

    Google Scholar 

  2. Parsons, R: Phosphatases and tumorigenesis. Curr Opin Oncol 10(l): 88–91, 1998

    Google Scholar 

  3. Draetta G, Eckstein J: Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta 1332(2): M53-M63, 1997

    Google Scholar 

  4. Eckstein J: Cdc25 protein phosphatase: regulation and its role in cancer Gene Ther Mol Biol 1: 707–711, 1998

    Google Scholar 

  5. Pines J: Cell cycle. Checkpoint on the nuclear frontier. Nature 397(6715): 104–105, 1999

    Google Scholar 

  6. Zornig M, Evan GI: Cell cycle: on target with Myc. Curr Biol 6(12): 1553–1556, 1996

    Google Scholar 

  7. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D: CDC25 phosphatases as potential human oncogenes. Science 269(5230): 1575–1577, 1995

    Google Scholar 

  8. Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S, Boiocchi M: Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res 57(12): 2366–2368, 1997

    Google Scholar 

  9. Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, Muntane J, Mallofre C, Montserrat E, Cardesa A, Campo E: cdc25 cell cycle-activating phosphatases and c-myc expression in human nonHodgkin's lymphomas. Cancer Res 58(8): 1762–1767, 1998

    Google Scholar 

  10. Galaktionov K, Chen X, Beach D: Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382(6591): 511–517, 1996

    Google Scholar 

  11. Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, Tahara E: Overexpression of cyclin-dependent kinaseactivating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res 88(10): 947–952, 1997

    Google Scholar 

  12. Wu W, Fan YH, Kemp BL, Walsh G, Mao L: Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 58(18): 4082–4085, 1998

    Google Scholar 

  13. Robinson SP, Perron D, Miller R, Parker L, Johnston C, Wei FY, Jin P, Tam S, Worland P, Wickramsinghe D, Voss J: Elevated levels of Cdc25A and C in human tumour cell lines. Proc Amer Assoc Cancer Res 40: #79, 19991 Reynolds et al. published a crystal structure of the catalytic subunit of Cdc25B (J Mol Biol 293: 559–568, 1999) which shows a different C-terminal conformation than the Cdc25A structure as well as a bound anion in the active site. 155

    Google Scholar 

  14. Russell P: Checkpoints on the road to mitosis. TIBS 23: 399–402, 1998

    Google Scholar 

  15. Furnari B, Rhind N, Russell P: Cdc25 mitotic inducer targeted by chkl DNA damage checkpoint kinase (see comments). Science 277(5331): 1495–1497, 1997

    Google Scholar 

  16. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ: Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25 (see comments). Science 277(5331): 1497–1501, 1997

    Google Scholar 

  17. Zeng Y, Forbes KC, Wu Z, Moreno S, Piwnica-Worms H, Enoch T: Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cdsl or Chk1. Nature 395(6701): 507–510, 1998

    Google Scholar 

  18. Kumagai A, Yakowec PS, Dunphy WG: 14–3–3 proteins act as negative regulators of the mitotic inducer Cdc25 in Xenopus egg extracts. Mol Biol Cell 9(2): 345–354, 1998

    Google Scholar 

  19. Lopez-Girona A, Furnari B, Mondesert O, Russell P: Nuclear localization of Cdc25 is regulated by DNA damage and a 14–3–3 protein (see comments). Nature 397(6715): 172–175, 1999

    Google Scholar 

  20. Peng CY, Graves PR, Ogg S, Thoma RS, Byrnes MJ, 3rd, Wu Z, Stephenson MT, Piwnica-Worms H: C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14–3–3 protein binding. Cell Growth Differ 9(3): 197–208, 1998

    Google Scholar 

  21. Wickramasinghe D, Palka ME, Reid S, Tessarollo L, Donovan PJ: The role of Cdc25B during mouse development. Keystone Symposia on Growth Control Abstract: 147, 1997

  22. Ashcroft NR, Kosinski ME, Wickramasinghe D, Donovan PJ, Golden A: The four cdc25 genes from the nematode Caenorhabditis elegans. Gene 214(1–2): 59–66, 1998

    Google Scholar 

  23. Ashcroft NR, Srayko M, Kosinski ME, Mains PE, Golden A: RNA-Mediated interference of a cdc25 homolog in Caenorhabditis elegans results in defects in the embryonic cortical membrane, meiosis, and mitosis. Dev Biol 206(l): 15–32, 1999

    Google Scholar 

  24. Galaktionov K and Beach D: Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 67(6): 1181–1194, 1991

    Google Scholar 

  25. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, Okayama H: Cdc25A is a novel phosphatase functioning early in the cell cycle. Embo J 13(7): 1549–1556, 1994

    Google Scholar 

  26. Hoffmann I, Draetta G, Karsenti E: Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the GI /S transition. Embo J 13(18): 4302–4310, 1994

    Google Scholar 

  27. Garner-Hamrick PA, Fisher C: Antisense phosphorothioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persistent antiproliferative effects. Int J Cancer 76(5): 720–728, 1998

    Google Scholar 

  28. Fauman EB, Cogswell JP, Lovejoy B, Rocque WJ, Holmes W, Montana VG, Piwnica-Worms H, Rink MJ, Saper MA: Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell 93(4): 617–625, 1998

    Google Scholar 

  29. Walker N, Borhani D, Fujimori T, Bettencourt B, Taylor, Neil, Rudolph J, Epstein D, Bottomley S, Eckstein JW: The crystal structure of a catalytic domain of human Cdc25. unpublished, 1997

  30. Fauman EB, Saper MA: Structure and function of the protein tyrosine phosphatases. Trends Biochem Sci 21(11): 413–417, 1996

    Google Scholar 

  31. Eckstein JW, Beer-Romero P, Berdo I: Identification of an essential acidic residue in Cdc25 protein phosphatase and a general three-dimensional model for a core region in protein phosphatases. Protein Sci 5(1): 5–12, 1996

    Google Scholar 

  32. Stuckey JA, Schubert HL, Fauman EB, Zhang ZY, Dixon JE, Saper MA: Crystal structure of Yersinia protein tyrosine phosphatase at 2.5 A and the complex with tungstate (see comments). Nature 370(6490): 571–575, 1994.

    Google Scholar 

  33. Hofmann K, Bucher P, Kajava AN: A model of Cdc25 phosphatase catalytic domain and Cdk-interaction surface based on the presence of a rhodanese homology domain. J Mol Biol 282(l): 195–208, 1998

    Google Scholar 

  34. Gottlin EB, Xu X, Epstein DM, Burke SP, Eckstein JW, Ballou DP, Dixon JE: Kinetic analysis of the catalytic domain of human cdc25B. J Biol Chem 271(44): 27445–27449, 1996

    Google Scholar 

  35. Eckstein JW: From sequence to function-structural motifs of cell cycle proteins., in Cell Cycle-Materials and Methods, M. Pagano, Editor. Springer: Berlin/Heidelberg/New York. 186–199, 1995

    Google Scholar 

  36. Fauman EB, Yuvaniyama C, Schubert HL, Stuckey JA, Saper MA: The X-ray crystal structures of Yersinia tyrosine phosphatase with bound tungstate and nitrate. Mechanistic implications. J Biol Chem 271(31): 18780–18788, 1996

    Google Scholar 

  37. Faure R, Vincent M, Dufour M, Shaver A, Posner BI: Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line. J Cell Biochem 59(3): 389–401, 1995

    Google Scholar 

  38. Imoto M, Kakeya H, Sawa T, Hayashi C, Hamada M, Takeuchi T, Umezawa K: Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. 1. Taxonomy, isolation, and characterization (published erratum in J Antibiot (Tokyo) 1994 Feb;47(2):C-1). J Antibiot (Tokyo) 46(9): 1342–1346, 1993

    Google Scholar 

  39. Caselli A, Camici G, Manao G, Moneti G, Pazzagli L, Cappugi G, Ramponi G: Nitric oxide causes inactivation of the low molecular weight phosphotyrosine protein phosphatase. J Biol Chem 269(40): 24878–24882, 1994

    Google Scholar 

  40. Caselli A, Chiarugi P, Camici G, Manao G, Ramponi G: In vivo inactivation of phosphotyrosine protein phosphatases by nitric oxide. FEBS Lett 374(2): 249–252, 1995

    Google Scholar 

  41. Wright AE, McCarthy PJ, Schulte GK: Sulfircin: A new sesterterpene sulfate from a deep-water sponge of the genus Ircinia. J Org chem (54): 3472–3474, 1989

  42. Cebula RE, Blanchard JL, Boisclair MD, Mansuri MM, Pal K, Bockovich NJ: Synthesis and phosphatase activity of analogs of sulfircin. Bioorg Med Chem Letters 7: 2015–2020, 1997

    Google Scholar 

  43. Burke TR Jr, Zhang ZY: Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers 47(3): 225–241, 1998

    Google Scholar 

  44. Kole HK, Akamatsu M, Ye B, Yan X, Barford D, Roller PP, Burke TR Jr: Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl. mimetic, LO-malonyltyrosine. Biochem Biophys Res Commun 209(3): 817–822, 1995

    Google Scholar 

  45. Groves MR, Yao ZJ, Roller PP, Burke TR Jr, Barford D: Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry 37(51): 17773–17783, 1998

    Google Scholar 

  46. Morino T, Shimada K, Masuda A, Yamashita N, Nishimoto M, Nishikiori T, Saito S: Structural determination of stevastelins, novel depsipeptides from Penicilliums J Antibiot (Tokyo) 49(6): 564–568, 1996

    Google Scholar 

  47. Horiguchi T, Nishi K, Hakoda S, Tanida S, Nagata A, Okayama H: Dnacin Al and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity. Biochem Pharmacol 48(11): 2139–2141, 1994

    Google Scholar 

  48. Hamaguchi T, Sudo T, Osada H: RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at Glphase. FEBS Lett 372(1): 54–58, 1995

    Google Scholar 

  49. Ni R, Nishikawa Y, Carr BI: Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. J Biol Chem 273(16): 9906–9911, 1998

    Google Scholar 

  50. Gunasekera SP, McCarthy PJ, Kelly-Borges M: Dysidiolide: A novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J Am Chem Soc 118: 8795–8796, 1996

    Google Scholar 

  51. Blanchard JL, Epstein DM, Boi clair M, Rudolph J, Eckstein J, Pal K: Dysidiolide and Related-hydroxy Butenolide Inhibitors of the Human Dual Specificity Protein-Tyrosine Phosphatase Cdc25. Bioorg Med Chem Letters, 1999, in press

  52. Peng H, Zalkow LH, Abraham RT, Powis G: Novel CDC25A Phosphatase Inhibitors from Pyrolysis of 3-a-Azido-B-homo-6-oxa-4-cholesten-7-one on Silica Gel J Med Chem 41(24): 4677–4680, 1998

    Google Scholar 

  53. Koufaki M, Polychroniou V, Calogeropoulou T, Tsotinis A, Drees M, Fiebig HH, LeClerc S, Hendriks HR, Makriyannis A: Alkyl and alkoxyethyl antineoplastic phospholipids. J Med Chem 39 (13): 2609–2614, 1996

    Google Scholar 

  54. Ham SW, Park J, Lee SJ, Kim W, Kang K, Choi KH: Naphthoquinone analogs as inactivators of cdc25 phosphatase. Bioorg Med Chem Lett 8(18): 2507–2510, 1998

    Google Scholar 

  55. el-Subbagh HI, Abadi AH, al-Khawad IE, al-Rashood KA: Synthesis and antitumor activity of some new substituted quinolin-4-one and 1,7-naphthyridin-4-one analogs. Arch Pharm (Weinheim) 332(1): 19–24, 1999

    Google Scholar 

  56. Abadi AH: 5-substituted 2-bromoindolo(3,2-blquinoxalines-A class of potential antitumor agents with cdc25 phosphatase inhibitory properties. Arch Pharm (Weinheim) 331(11): 352–358, 1998

    Google Scholar 

  57. Moran EJ, Sarshar S, Cargill JF, Shahbaz MM, Lio A, Mjalli AMM, Armstrong R: Radio frequency tag encoded combinatorial library method for the discovery of tripeptide-substituted cinnamic acid inhibitors of protein tyrosine phosphatase PTP1B. J Am Chem Soc 117: 10787–10788, 1995

    Google Scholar 

  58. Rice RL, Rusnak JM, Yokokawa F, Yokokawa S, Messner DJ, Boynton AL, Wipf P, Lazo JS: A targeted library of smallmolecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry 36(50): 15965–15974, 1997

    Google Scholar 

  59. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, ZhangSun G, Fantus IG, Ng JB, Hall DA, Lum BS, Shaver A: Peroxovanadium. Compounds: A new class of potent phosphotyrosine inhibitors which are insulin mimetics. J Biol Chem 269(6): 4596–4604, 1994

    Google Scholar 

  60. Suttie JW: Synthesis of vitamin K-dependent proteins. FASEB J 7(5): 445–452, 1993

    Google Scholar 

  61. Juan CC, Wu FY: Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34cdc2 kinase and phosphatase. Biochem Biophys Res Commun 190(3): 907–913, 1993

    Google Scholar 

  62. Unger C, Damenz W, Fleer EAM, Kim DJ, Breiser A, Hilgard P, Engel J, Nagel G, Eibl H: Hexadecylphosphocholine, a new ether lipid analogue. Acta Oncol 28: 213–217, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Enanta Pharmaceuticals, Cambridge, MA, USA

    Jens W. Eckstein

Authors
  1. Jens W. Eckstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eckstein, J.W. Cdc25 as a Potential Target of Anticancer Agents. Invest New Drugs 18, 149–156 (2000). https://doi.org/10.1023/A:1006377913494

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006377913494

Search

Navigation